Stock Market Today, Feb. 19 -- Indian pharma stocks faced significant selling pressure in today's session, February 19, after U.S. President Donald Trump announced that he would impose duties on pharmaceutical imports, expanding his ongoing trade protectionist measures to major industries.

Indian pharma stocks were already reeling under pressure due to weak performance in the December quarter, and rich valuations in some stocks had led to profit booking. With the latest tariff threats from the U.S., analysts believe that the pain in these stocks will continue until clarity emerges on the tariffs on pharma imports.

Nineteen out of 20 constituents of the Nifty Pharma index traded in the red, with Aurobindo Pharma and Lupin emerging as the...